There is a need in rheumatoid arthritis to be able to individualize treatments, but without credible and reliable biomarkers, it just isn't possible yet, said Allan Gibofsky, MD, professor of medicine and public health at Weill Cornell Medical College and an attending rheumatologist at Hospital for Special Surgery.
There is a need in rheumatoid arthritis to be able to individualize treatments, but without credible and reliable biomarkers, it just isn't possible yet, said Allan Gibofsky, MD, professor of medicine and public health at Weill Cornell Medical College and an attending rheumatologist at Hospital for Special Surgery.
Transcript (slightly modified)
What are the current challenges in rheumatoid arthritis treatment?
I think among the more significant challenges are the ability to predict who will do well and who will not. We haven't yet evolved to the stage where we have credible and reliable biomarkers to allow us to individualize therapy—perhaps someday we will. But for now, despite our guidelines and despite our recommendations, we're still acting empirically in the choice of therapies.
What developments would you like to see in rheumatoid arthritis medication?
I would love to see a medication that helps all people, all times, whenever they take it with no toxicity whatsoever. I would also also like to see a balanced budget and world peace. And I'm realistic to realize that just as I probably won't see the latter, we're not going to have a medication that is going to be effective for everyone without any side effects at all.
Consequently, what we really need are medications that can be individualized for a given patient to either enhance efficacy or minimize toxicity from the individual agent.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More